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ABSTRACT
Recent reports regarding the significance of chemokine
receptors in disease have put a spotlight on atypical chemokine
receptor 3 (ACKR3). This atypical chemokine receptor is
overexpressed in numerous cancer types and has been
involved in the modulation of tumor cell proliferation and
migration, tumor angiogenesis, or resistance to drugs, thus
contributing to cancer progression and metastasis occur-
rence. Here, we focus on the clinical significance and potential
mechanisms underlying the pathologic role of ACKR3 in
breast, lung, and brain cancer and discuss its possible
relevance as a prognostic factor and potential therapeutic
target in these contexts.
Introduction
ACKR3 (atypical chemokine receptor 3, also known as
CXCR7) is a seven-transmembrane domain atypical chemo-
kine receptor that belongs to class A of G protein–coupled
receptors. Both C-X-C motif chemokine 12 (CXCL12) and
C-X-C motif chemokine 11 (CXCL11) bind to the receptor.
CXCL12also binds toCXCR4 (C-X-C chemokine receptor type 4),
and likewise, CXCL11 binds to CXCR3, another chemokine
receptor of this family. Since the first description of ACKR3 as a
coreceptor for human immunodeficiency virus entry (Shimizu
et al., 2000), it has become clear that this receptor has a
prominent role in many pathologic contexts. ACKR3 expres-
sion was found to be upregulated in a variety of pathologic
conditions related to inflammation, infection, or ischemia.
For instance, ACKR3 expression is increased in inflamma-
tory bowel disease, encephalitis, rheumatoid arthritis, acute
renal failure, Epstein-Barr virus type I infection, or after
permanent middle cerebral artery occlusion (Sánchez-Martín
et al., 2013). Importantly, altered ACKR3 expression pat-
terns have also been detected in numerous cancer types, such
as prostate, kidney, liver, cervix, brain, lung, and breast
cancer [reviewed by Sánchez-Martín et al. (2013) and Freitas
et al. (2014)]. In this review, we focus on the evidence linking
altered ACKR3 expression with the progression of breast,
lung, and glioma tumors and discuss the underlyingmolecular
mechanisms.
ACKR3 in Breast Cancer. Breast cancer is the most
prevalent cancer among women worldwide (Siegel et al.,
2016). Several studies describe an association between the
CXCL12-ACKR3 axis and disease progression and poor over-
all survival of breast cancer patients. As a result, interest in
this receptor is markedly increasing, as it may be a potential
therapeutic target. Previous reports indicated that ACKR3
expression in breast cancer patient samples (in situ and
invasive lobular carcinomas) is much higher when compared
with adjacent tissues and normal mammary epithelium. This
was verified at protein and mRNA levels (Miao et al., 2007;
Wani et al., 2014; Li et al., 2015; Behnam Azad et al., 2016).
High expression was also detected in metastatic tissues
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(Wu et al., 2016; Yu et al., 2017b). Notably, ACKR3 over-
expression correlates with poor prognosis and lung metastasis–
free survival (Behnam Azad et al., 2016; Wu et al., 2016;
Yu et al., 2017b).
Furthermore, there is an association between higher
levels of ACKR3 and worse outcomes in terms of disease-free
survival (Hassan et al., 2009), and a positive correlation
between ACKR3 expression level and lymph node metastasis:
ACKR3 expression is higher in primary tumors of patients
with lymphatic metastasis than in those of metastasis-free
patients (Li et al., 2015). Taken together, these findings
indicate that ACKR3 plays a role in breast cancer progression
and metastasis occurrence.
Several in vitro and in vivo studies have found that higher
levels of ACKR3 result in increased cell proliferation and
invasive migration, promoting tumor growth and metastasis
(Miao et al., 2007; Xue et al., 2013; Gao et al., 2015; Li et al.,
2015). However, the molecular mechanisms linking enhanced
ACKR3 expression to these processes are not fully elucidated.
Research performed in model cell lines with ectopically
overexpressed ACKR3 and CXCR4 receptors or in different
cell types with endogenous levels of these proteins has put
forward several potential mechanisms. In mouse migrating
interneurons, ACKR3 has been shown to be key for migration
by scavenging CXCL12, thus preventing coexpressed CXCR4
from desensitization and degradation and allowing adequate
levels of CXCL12-CXCR4 signaling (Sánchez-Alcañiz et al.,
2011; Abe et al., 2014). These data suggest that high ACKR3
expression in breast cancer would foster CXCR4-dependent
cascades. Such a scavenging role is related to constitutive and
ligand-dependent ACKR3 internalization and recycling ob-
served in different cell types (Naumann et al., 2010), including
breast cancer cells (Luker et al., 2010). This allows receptor
trafficking to lysosomes and degradation of receptor-bound
CXCL12 (Luker et al., 2010; Naumann et al., 2010; Hoffmann
et al., 2012). Consistent with this notion, uptake of CXCL12 by
ACKR3-positive (ACKR31) breast cancer cells increases pro-
liferation and metastatic potential of CXCR41 cells (Luker
et al., 2012). Interestingly, ACKR3 ligands trigger b-arrestin
recruitment to the receptor in model cell systems (Luker
et al., 2009b; Rajagopal et al., 2010; Benredjem et al., 2017),
and it has been reported that ACKR3 internalization and
the resulting chemokine degradation are dependent on
b-arrestin in breast cancer cells (Luker et al., 2010). How-
ever, constitutive receptor internalization and recycling can
also take place in a ligand-independent way. Recent data
show that b-arrestins are dispensable for chemokine scav-
enging (Montpas et al., 2018), suggesting that other ACKR3-
interacting proteins might be involved in the internalization
process, depending on the experimental conditions and
cellular context.
In addition to its ligand-scavenging properties, it cannot be
ruled out that the interaction of ACKR3 with b-arrestins (or
other interacting proteins to be identified) may also trigger
other downstream cascades in a cell-type-specific way (Sánchez-
Alcañiz et al., 2011). ACKR3 recruitment of b-arrestins might
also modify CXCR4 signaling by recruiting b-arrestin2 away
from coexpressed CXCR4 (Coggins et al., 2014) or via
ACKR3/CXCR4 cointernalization, as reported inMCF7 breast
cancer cells (Sánchez-Martín et al., 2013).
Therefore, it is tempting to suggest that both CXCR4 and
ACKR3 cooperate to promote tumor growth and metastasis
through different interaction and cross-talk mechanisms
(Sierro et al., 2007; Levoye et al., 2009; Luker et al., 2009a,
2010). While some reports have indicated that CXCR4 is
overexpressed in breast cancer patient samples, with both
receptors colocalized (Inaguma et al., 2015), others have
shown that CXCR4 and ACKR3 are predominantly expressed
on separated populations of breast cancer cells (Luker et al.,
2012). Additionally, CXCR4 and ACKR3 coexpression in the
MTLn3 breast cancer cell line decreases invasion in response
to CXCL12 (Hernandez et al., 2011). Given the discrepancies
in the available data, further investigating whether CXCR4
and ACKR3 are expressed in the same or distinct subpopula-
tions of breast cancer cells is key to better understanding
these potential cross-talk mechanisms.
In addition to CXCR4, ACKR3 may also functionally inter-
act with other key signaling cascades in breast cancer, such as
estrogen and epidermal growth factor receptors. Analysis of
luminal-type breast cancer tumor samples revealed a positive
correlation between ACKR3 and estrogen receptor (ER) levels.
Overexpression of ACKR3 can result in increased estrogen
signaling in ER1 breast tumor cells and is closely related to
tamoxifen insensitivity, which would make ACKR3 a relevant
target specifically inER-positive breast cancer (Hao et al., 2018).
ACKR3 and epidermal growth factor receptor (EGFR) have
also been found to be colocalized in ER1 breast cancer tissues.
In vitro studies show that EGFR expression correlates with
ACKR3 levels in breast cancer cell lines and, interestingly,
that EGFR is absent in cells lacking ACKR3. Furthermore,
partial depletion of ACKR3 in a breast cancer cell line results
in decreased proliferation in response to epidermal growth
factor and decreased activation of the extracellular signal-
regulated kinase pathway and level of EGFR phosphorylation.
These findings strongly suggest a cooperation between both
receptors in tumor proliferation (Salazar et al., 2014).
In addition to the aforementioned roles involving other
receptors, ACKR3 has an independent effect on cell cycle or
apoptosis-related cascades in breast cancer cells. Decreasing
ACKR3 levels alters expression of cell cycle–related proteins
and leads to cell cycle arrest, hence reducing cell proliferation
(Salazar et al., 2014). Additionally, knock down of the receptor
in the MCF7 breast cancer cell line increased the expression
of the proapoptotic caspase 3 and 8 proteins (Gao et al., 2015).
In addition, ACKR3 expression enhances breast cancer pro-
liferation through signal transducer and activator of tran-
scription 3 activation, which has previously been linked to
apoptosis resistance and cell cycle progression in invasive
breast cancer (Wani et al., 2014; Li et al., 2015).
Another key event in breast cancer is cell migration and
invasion, ultimately leading to metastasis occurrence, which
is the primary cause of death of the majority of breast cancer
patients. Migration and invasion events require degradation
of basement membrane extracellular matrix proteins by
matrix metalloproteinases (MMPs). ACKR3 expression is as-
sociated with the secretion ofMMP2,MMP3, andMMP9 (Zabel
et al., 2010; Gao et al., 2015). ACKR3 overexpression also
accompanies mesenchymal-to-epithelial transition, a pathway
leading to metastatic events (Leontovich et al., 2012).
In addition to metastasis, breast cancer stem cells (bCSCs),
a population of cells located within the tumor with high
proliferative capacity and exhibiting resistance to therapeu-
tics, are a current challenge for breast cancer–targeted
therapies. It was demonstrated that ACKR3 is crucial for












tumorigenicity and maintenance of stem cell properties of
bCSCs (Tang et al., 2016). Given the role of this receptor in
both metastasis and bCSCs within the primary tumor, it
appears to be an attractive target for new therapeutic ap-
proaches for breast cancer.
Accumulating evidence suggests that ACKR3 also plays
a pivotal role in tumor-associated vasculature. One study
assessing ACKR3 expression in tumor samples (BehnamAzad
et al., 2016) showed an intense vascular staining specifically in
the endothelium of tumor-associated blood vessels. In con-
trast, the receptor was not expressed in healthy tissue blood
vessels. Another report demonstrated that concomitant ex-
pression of ACKR3 in tumor and tumor-associated vascula-
ture promotes cell-cell interaction (Miao et al., 2007),
suggesting a role for this receptor in modulating cell adhesion
in the tumor microenvironment. ACKR3 also enhances vas-
cular cell-adhesion molecule-1 expression (Wani et al., 2014).
Since tumor cell adhesion to the basal membrane is crucial for
the invasive process, these data suggest that ACKR3mediates
this step. Furthermore, a recent study showed that ACKR3
downregulation decreases vascular endothelial growth factor
production and tube formation (Qian et al., 2018), suggesting
a role for this receptor in angiogenesis, an important event
that leads to tumor cell survival and migration. Nevertheless,
another report using a different experimental model suggested
that vascular ACKR3 suppresses tumor proliferation and
decreases metastatic potential of tumor cells (Stacer et al.,
2016). These discrepancies may be explained by the different
models used in each study or might suggest a context-
dependent role for ACKR3 that requires further investigation.
On the other hand, it is worth noting that ACKR3 also
increases tumor-promoting macrophages and recruitment to
the tumor site (Wani et al., 2014), a key event in determining
the tumor microenvironment.
In summary, these studies point to a pivotal role for
ACKR3 in breast cancer progression and metastasis by
promoting survival, proliferation, and migration of malig-
nant cells. Moreover, ACKR3 modulates angiogenic path-
ways and helps to shape the tumor microenvironment, thus
further controlling tumor growth (Fig. 1). Although more
studies are needed to clarify the exact mechanisms by which
ACKR3 operates, accumulating evidence strongly indicates
that ACKR3 is a potential therapeutic target in breast cancer.
ACKR3 in Lung Cancer. Lung cancer is the most fre-
quent cause of cancer-related death in men and the second
most frequent in women. Initial studies on ACKR3 reported
an increased expression of ACKR3 in malignant lung carci-
noma biopsy material when compared with healthy human
lung samples (Burns et al., 2006). Further analysis of ACKR3
expression in multiple cancer types, including lung squamous
cell carcinoma, showed localized ACKR3 staining on the
tumor vasculature. These first findings suggested a role for
ACKR3 in lung cancer (Miao et al., 2007), which was further
investigated in vivo using mice engrafted with mouse Lewis
lung carcinoma cells or human lung carcinoma cells. These
studies demonstrated that both diminishing ACKR3 expres-
sion and inhibiting ACKR3 signaling by the ACKR3 ligand
CCX754 resulted in decreased tumor growth. Interestingly,
the extent to which CCX754 decreased tumor growth was
almost similar to the marketed chemotherapy drug melpha-
lan, showing the potential for targeting ACKR3 in lung cancer
(Burns et al., 2006; Miao et al., 2007).
ACKR3 expression is found in many types of lung cancer.
Investigation of human biopsy material indicates expres-
sion in small-cell lung cancer (Imai et al., 2010) and the
non–small-cell lung cancer (NSCLC) subtypes adenocarci-
noma, squamous cell carcinoma, and large-cell carcinoma
(Miao et al., 2007; Goldmann et al., 2008; Iwakiri et al.,
2009; Imai et al., 2010; Franco et al., 2012).
Within the Human Protein Atlas program, a recent initia-
tive to define the oncological proteome, mRNA expression
levels of ACKR3 were investigated in 794 lung cancer biopsies
(Uhlen et al., 2017). Comparison of the expression of ACKR3
with overall survival rate of patients showed an unfavorable
outcome for high ACKR3 expression. This trend did not have
the statistical power to be used for prognostic purposes, but it
highlights the relevance of ACKR3 expression in lung cancer
(Uhlen et al., 2017).
Surgical removal of lung tumors is one of the standard
treatment procedures for lung cancer. However, tumor recur-
rence is often observed and is related to poor prognosis
(Pearson, 1999). A study of ACKR3 mRNA expression in the
surgical specimens from 79 patients who underwent complete
resection showed that ACKR3 mRNA expression could be
used as a postoperative 5-year disease-free prognostic marker
in stage I NSCLC patients. Furthermore, there was a signif-
icantly higher ACKR3 expression in pathologic stage INSCLC
patients with postoperative recurrence of secondary tumors
compared with recurrence-free patients (Iwakiri et al., 2009).
These results suggest that ACKR3 may be related to the
process by which NSCLC forms secondary tumors.
A factor that has been linked to metastasis and, thus, the
formation of secondary tumors of lung cancer is transforming
growth factor b1 (TGF-b1) (Massagué, 2008). The mRNA and
protein expression of ACKR3 is regulated by TGF-b1, and the
combination of high TGF-b1 andACKR3 expression correlates
with poor patient survival (Wu et al., 2016). TGF-b1–mediated
functional effects, including cancer cellmotility and epithelial-
to-mesenchymal transition, appear to depend on ACKR3
(Massagué, 2008; Wu et al., 2016). Furthermore, epithelial-
to-mesenchymal transition of cancer cells leads to the formation
of cancer stem cells which show high metastatic properties
(Singh and Settleman, 2010), and TGF-b1 induces cancer stem
cell formation in an ACKR3-dependent manner (Wu et al.,
2016). Collectively, these findings suggest a key role of ACKR3
in cancer stem cell formation, what might underlie ACKR3-
mediated formation of secondary tumors.
In lung cancer, mutations in the EGFR, KRAS, and ALK
genes are mutually exclusive and can be used to define respon-
siveness to different chemotherapies. A study on the presence
of EGFR mutations showed that ACKR3 mRNA expression is
higher in lung cancer patients with mutated EGFR compared
with wild-type EGFR patients, suggesting a role for ACKR3 in
EGFR-mediated lung cancer (Iwakiri et al., 2009). Further-
more, an in vivo study in which Lkb1 and Pten were
conditionally knocked down in mice showed that this leads
to development of the lung cancer subtype squamous cell
carcinoma (Xu et al., 2014). Transcriptomics data of the Lkb1
(2/2)/Pten (2/2) squamous cell carcinoma tumor showed an
increase in ACKR3 expression when compared with healthy
lung tissue, suggesting a role of ACKR3 in Lkb1/Pten-
mediated lung cancer (Xu et al., 2014). Altogether, these
observations suggest a universal role of ACKR3 in multiple
lung cancer subtypes.












Fig. 1. Graphical representation illustrating the role of ACKR3 in cancer. See text for details. EMT, epithelial-mesenchymal transition; STAT3, signal
transducer and activator of transcription 3; VCAM-1, vascular cell-adhesion molecule-1; VEGF, vascular endothelial growth factor.












ACKR3 in Glioma. The term glioma encloses a variety of
intrinsic central nervous system tumors. These tumors were
initially classified based on their presumed cellular origin
(astrocytoma, oligodendroglioma, oligoastrocytoma) and ex-
tension of infiltration (diffuse or nondiffuse glioma). Regard-
less of the subclassification, glioma are divided into three
malignancy grades (II, III, and IV) considering their mi-
totic activity, necrosis, and florid microvascular proliferation.
Glioblastoma is the most malignant one (grade IV) and is
categorized as either “secondary” or “primary,” depending on
whether there is evidence of a progression from a lower-grade
glioma. However, in 2016, the World Health Organization
(WHO) introduced a genotypic classification based on the
presence of recurrent point mutations in isocitrate dehydro-
genase 1 and 2 (IDH1/IDH2) genes, dividing glioblastoma into
glioblastoma-IDH-wild type and glioblastoma-IDH-mutant.
Interestingly, the majority of secondary glioblastoma are
IDH-mutants, whereas primary glioblastoma are typically
IDH-wild type (Parsons et al., 2008). Recently, it was proposed
that ACKR3 influences prognosis in human glioma, depending
on the IDH classification (Birner et al., 2015). In fact, ACKR3
expression in tumor-associated vessels predicts a better prog-
nosis in IDH1-wild-type glioma, whereas it has opposite conse-
quences in the IDH1-mutant subtype. In addition, mRNA as
well as protein levels of ACKR3 were found to be upregu-
lated in glioma (Calatozzolo et al., 2011) and to positively
correlate with WHO grade in several studies (Hattermann
et al., 2010; Walters et al., 2014; Bianco et al., 2015; Birner
et al., 2015). ACKR3 localization also changes with WHO
grade. In fact, in grade II glioma, ACKR3 is mainly expressed
in cancer cells. In grade III, it is present primarily in tumor
vascular endothelial cells and only marginally in cancer cells.
In glioblastoma, ACKR3 is found in cancer cells, in pseudopa-
lisades nearest to necrotic areas, and in the tumor endothe-
lium (Bianco et al., 2015). Standard care for the treatment of
WHO grade III and IV glioma consists of surgery followed by
chemotherapy (temozolomide) that can be combined with
intermediate-frequency alternating electric fields (Touat
et al., 2017). However, glioma exhibit both radio (Han et al.,
2017) and drug resistance (Stavrovskaya et al., 2016), making
the current therapies ineffective, with a median survival
ranging from 12 to 16 months after diagnosis (Gilbert et al.,
2014). Accumulating evidence suggests that ACKR3 might
play a role in these acquired resistances. In fact, CXCL12
reverses the antiproliferative effect of nontoxic concentrations
of temozolomide in C6 rat cells isolated from murine glioma
(Hattermann et al., 2012). Accordingly, CXCL12 also re-
duces temozolomide-induced apoptosis. These CXCL12 effects
might involve ACKR3, which is expressed at a much higher
level than CXCR4 in C6 cells. Corroborating these findings,
the presence of the ACKR3 modulator CCX771 after irradia-
tion provokes tumor regression in nude mice injected with
U251 glioma cells (Walters et al., 2014). In addition, treatment
with the ACKR3 ligand CCX662 (able to induce b-arrestin
recruitment to ACKR3 and inhibit CXCL12-dependent mi-
gration) extends the survival of rats with nitrosourea-induced
brain tumors after irradiation. However, in a more aggressive
model consisting of the injection of C6 glioma cells in rats, only
the combination of irradiation with CCX662 treatment ex-
tends survival.
Contradictory results are emerging regarding the role of
ACKR3 in glioma cell proliferation. In fact, in the U373
glioblastoma cell line and in human fetal astrocytes,
CXCL12-induced proliferation is prevented by the ACKR3
ligand CCX733 (Calatozzolo et al., 2011). On the other hand,
CXCL12 does not influence either proliferation ormigration of
A764 and U343 glioma cells (Hattermann et al., 2010). More-
over, in cocultures of U87 cells and human brain microvascu-
lar endothelial cells, the receptor was found to have no trophic
effect (Rao et al., 2012). Long noncoding RNA X-inactive-
specific transcript is upregulated in glioma endothelial cells
forming the blood-tumor barrier (Yu et al., 2017a) and
increases glioma angiogenesis by indirectly controlling
ACKR3 expression. In fact, the study showed that down-
regulation of X-inactive-specific transcript increases miRNA-
137 expression, which in turn inhibits the expression of
forkhead box C1, a transcription factor that promotes ACKR3
expression.
The common view of ACKR3 as an atypical chemokine
receptor unable to activate G proteins (Naumann et al., 2010)
was challenged in 2012 when it was suggested that the
receptor can signal through Gi/o proteins in astrocytes and
human glioma cells (Odemis et al., 2010). This study showed
that CXCL12 induces activation of G proteins and Ca21 influx
in rat astrocytes in primary culture. Both effects persisted in
cultures obtained from CXCR4 knockout mice and were
abolished by pretreatment of cells with an ACKR3 small
interfering RNA. Moreover, both CXCL12-induced prolifera-
tion and migration of rat astrocytes did not require CXCR4
expression and were inhibited by pertussis toxin, suggesting
that ACKR3 influences migration and proliferation of astro-
cytes in a G protein–dependent fashion. On the other hand, in
the same study, CXCL11did not activateGproteins, suggesting
that the ability of ACKR3 to activate G proteins in astrocytes
depends on the nature of the agonist. So far, the ability of
ACKR3 to activate G proteins has only been found in glial cells
and not in other cell types (Levoye et al., 2009; Rajagopal et al.,
2010; Kumar et al., 2012). This unique capability of glial
ACKR3 to activate G proteins certainly warrants further
exploration, providing that it is confirmed in independent
studies. In another study, CXCL12 also triggered mitogen-
activated protein kinase phosphorylation in glioma cells via
phospholipase C but not AKT and p38 (Hattermann et al.,
2010). Whether this effect requires ACKR3 coupling to G
proteins has not been investigated.
Collectively, previously published data show a high ACKR3
expression in glioma and glioma cell lines. Although its role in
the progression of this cancer type and the underlying
signaling mechanisms need to be fully characterized, avail-
able data indicate that this receptor plays an important role in
glioma drug/radio resistance and angiogenesis.
Conclusions
Extended literature analysis points to a pivotal role of
ACKR3 in breast, lung, and brain cancers. Expression of this
atypical chemokine receptor, both at mRNA and protein
levels, is higher in tumor samples when compared with
healthy tissues. Moreover, increasing evidence indicates that
receptor expression positively correlates with poor prognosis,
disease grade, and reoccurrence, making it a valuable bio-
marker for diagnosis and prognosis in certain breast, lung,
and brain cancer types. ACKR3 is also emerging as a key
player of cancer progression and metastasis occurrence via












actions on both tumor cells (favoring cell proliferation and
invasion) and the tumor microenvironment by modulating
angiogenesis (Fig. 1). The use of relevant animal or cellular
models with endogenous levels of chemokine receptors will
allow a better knowledge of the molecular mechanisms in-
volved, the stimuli leading to ACKR3 overexpression in cancer
contexts, and the cross-talk of ACKR3 with key oncogenic
signaling cascades. Insight into thesemechanisms is essential
to help develop new strategies to limit tumor progression and
avoid resistance to therapy.
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